136 related articles for article (PubMed ID: 37395026)
1. CRISPR/Cas9-Mediated Gene Correction in Osteopetrosis Patient-Derived iPSCs.
Li D; Ou M; Zhang W; Luo Q; Cai W; Mo C; Liang W; Dai G; Yin L; Zhu P; Tang D; Dai Y
Front Biosci (Landmark Ed); 2023 Jun; 28(6):131. PubMed ID: 37395026
[TBL] [Abstract][Full Text] [Related]
2. Genotyping, generation and proteomic profiling of the first human autosomal dominant osteopetrosis type II-specific induced pluripotent stem cells.
Ou M; Li C; Tang D; Xue W; Xu Y; Zhu P; Li B; Xie J; Chen J; Sui W; Yin L; Dai Y
Stem Cell Res Ther; 2019 Aug; 10(1):251. PubMed ID: 31412925
[TBL] [Abstract][Full Text] [Related]
3. Osteopetrotic induced pluripotent stem cells derived from patients with different disease-associated mutations by non-integrating reprogramming methods.
Okur FV; Cevher İ; Özdemir C; Kocaefe Ç; Çetinkaya DU
Stem Cell Res Ther; 2019 Jul; 10(1):211. PubMed ID: 31315669
[TBL] [Abstract][Full Text] [Related]
4. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR/Cas9 and piggyBac transposon system.
Itoh M; Kawagoe S; Tamai K; Nakagawa H; Asahina A; Okano HJ
J Dermatol Sci; 2020 Jun; 98(3):163-172. PubMed ID: 32376152
[TBL] [Abstract][Full Text] [Related]
5. Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II.
Waguespack SG; Koller DL; White KE; Fishburn T; Carn G; Buckwalter KA; Johnson M; Kocisko M; Evans WE; Foroud T; Econs MJ
J Bone Miner Res; 2003 Aug; 18(8):1513-8. PubMed ID: 12929941
[TBL] [Abstract][Full Text] [Related]
6. Generation of a human induced pluripotent stem cell line (BIHi002-A) from a patient with CLCN7-related infantile malignant autosomal recessive osteopetrosis.
Hennig AF; Rössler U; Boiti F; von der Hagen M; Gossen M; Kornak U; Stachelscheid H
Stem Cell Res; 2019 Mar; 35():101367. PubMed ID: 30763735
[TBL] [Abstract][Full Text] [Related]
7. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
[TBL] [Abstract][Full Text] [Related]
8. Successful correction of factor V deficiency of patient-derived iPSCs by CRISPR/Cas9-mediated gene editing.
Nakamura T; Morishige S; Ozawa H; Kuboyama K; Yamasaki Y; Oya S; Yamaguchi M; Aoyama K; Seki R; Mouri F; Osaki K; Okamura T; Mizuno S; Nagafuji K
Haemophilia; 2020 Sep; 26(5):826-833. PubMed ID: 32700411
[TBL] [Abstract][Full Text] [Related]
9. Multiomics landscape of the autosomal dominant osteopetrosis type II disease-specific induced pluripotent stem cells.
Li C; Shangguan Y; Zhu P; Dai W; Tang D; Ou M; Dai Y
Hereditas; 2021 Oct; 158(1):40. PubMed ID: 34702373
[TBL] [Abstract][Full Text] [Related]
10. Correction of Hirschsprung-Associated Mutations in Human Induced Pluripotent Stem Cells Via Clustered Regularly Interspaced Short Palindromic Repeats/Cas9, Restores Neural Crest Cell Function.
Lai FP; Lau ST; Wong JK; Gui H; Wang RX; Zhou T; Lai WH; Tse HF; Tam PK; Garcia-Barcelo MM; Ngan ES
Gastroenterology; 2017 Jul; 153(1):139-153.e8. PubMed ID: 28342760
[TBL] [Abstract][Full Text] [Related]
11. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
[TBL] [Abstract][Full Text] [Related]
12. CRISPR/Cas9 mediated gene correction ameliorates abnormal phenotypes in spinocerebellar ataxia type 3 patient-derived induced pluripotent stem cells.
He L; Wang S; Peng L; Zhao H; Li S; Han X; Habimana JD; Chen Z; Wang C; Peng Y; Peng H; Xie Y; Lei L; Deng Q; Wan L; Wan N; Yuan H; Gong Y; Zou G; Li Z; Tang B; Jiang H
Transl Psychiatry; 2021 Sep; 11(1):479. PubMed ID: 34535635
[TBL] [Abstract][Full Text] [Related]
13. Naïve Induced Pluripotent Stem Cells Generated From β-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9.
Yang Y; Zhang X; Yi L; Hou Z; Chen J; Kou X; Zhao Y; Wang H; Sun XF; Jiang C; Wang Y; Gao S
Stem Cells Transl Med; 2016 Jan; 5(1):8-19. PubMed ID: 26676643
[TBL] [Abstract][Full Text] [Related]
14. Generation of a gene corrected human isogenic IBMS-iPSC-014-C from polycystic-kidney-disease induced pluripotent stem cell line using CRISPR/Cas9.
Liu CL; Huang CY; Chen HC; Lu HE; Hsieh PCH; Lee JJ
Stem Cell Res; 2020 May; 45():101784. PubMed ID: 32361310
[TBL] [Abstract][Full Text] [Related]
15. CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs.
Morishige S; Mizuno S; Ozawa H; Nakamura T; Mazahery A; Nomura K; Seki R; Mouri F; Osaki K; Yamamura K; Okamura T; Nagafuji K
Int J Hematol; 2020 Feb; 111(2):225-233. PubMed ID: 31664646
[TBL] [Abstract][Full Text] [Related]
16. Genetic Correction of Induced Pluripotent Stem Cells From a Deaf Patient With MYO7A Mutation Results in Morphologic and Functional Recovery of the Derived Hair Cell-Like Cells.
Tang ZH; Chen JR; Zheng J; Shi HS; Ding J; Qian XD; Zhang C; Chen JL; Wang CC; Li L; Chen JZ; Yin SK; Huang TS; Chen P; Guan MX; Wang JF
Stem Cells Transl Med; 2016 May; 5(5):561-71. PubMed ID: 27013738
[TBL] [Abstract][Full Text] [Related]
17. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.
Chu K; Snyder R; Econs MJ
J Bone Miner Res; 2006 Jul; 21(7):1089-97. PubMed ID: 16813529
[TBL] [Abstract][Full Text] [Related]
18. Both TALENs and CRISPR/Cas9 directly target the HBB IVS2-654 (C > T) mutation in β-thalassemia-derived iPSCs.
Xu P; Tong Y; Liu XZ; Wang TT; Cheng L; Wang BY; Lv X; Huang Y; Liu DP
Sci Rep; 2015 Jul; 5():12065. PubMed ID: 26156589
[TBL] [Abstract][Full Text] [Related]
19. Transcriptomic and bioinformatic analysis of Clcn7-dependent Autosomal Dominant Osteopetrosis type 2. Preclinical and clinical implications.
Norwood I; Szondi D; Ciocca M; Coudert A; Cohen-Solal M; Rucci N; Teti A; Maurizi A
Bone; 2021 Mar; 144():115828. PubMed ID: 33359007
[TBL] [Abstract][Full Text] [Related]
20. Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration.
Burnight ER; Gupta M; Wiley LA; Anfinson KR; Tran A; Triboulet R; Hoffmann JM; Klaahsen DL; Andorf JL; Jiao C; Sohn EH; Adur MK; Ross JW; Mullins RF; Daley GQ; Schlaeger TM; Stone EM; Tucker BA
Mol Ther; 2017 Sep; 25(9):1999-2013. PubMed ID: 28619647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
